KAT5 histone acetyltransferase mutations in cancer cells

Kimberly L Hardison¹, Tila M Hawk¹, Renee A Bouley¹§, Ruben C Petreaca¹§
¹The Ohio State University
§To whom correspondence should be addressed: bouley.8@osu.edu; petreaca.1@osu.edu

Abstract

Cancer cells are characterized by accumulation of mutations due to improperly repaired DNA damage. The DNA double strand break is one of the most severe form of damage and several redundant mechanisms have evolved to facilitate accurate repair. During DNA replication and in mitosis, breaks are primarily repaired by homologous recombination which is facilitated by several genes. Key to this process is the breast cancer susceptibility genes BRCA1 and BRCA2 as well as the accessory RAD52 gene. Proper chromatin remodeling is also essential for repair and the KAT5 histone acetyltransferase facilitates histone removal at the break. Here we undertook a pan cancer analysis to investigate mutations within the KAT5 gene in cancer cells. We employed two standard artificial algorithms to classify mutations as either driver (CHASMPlus algorithm) or pathogenic (VEST4 algorithm). We find that most predicted driver and disease-causing mutations occur in the catalytic site or within key regulatory domains. In silico analysis of protein structure using AlphaFold shows that these mutations are likely to destabilize the function of KAT5 or interactions with DNA or its other partners. The data presented here, although preliminary, could be used to inform clinical strategies.
Figure 1. KAT5 point mutation distribution in cancers
A. KAT5 point mutation type in all cancer tissues. B. Distribution of coding and non-coding (intronic, 5', and 3' UTR) KAT5 mutations by cancer type. C. KAT5 mutations with significant (p<0.05) CHASM and VEST p-values. CHASM predicted driver mutations are shown in green, VEST predicted pathogenic mutations are shown in red and mutations that are predicted to be both driver and pathogenic are shown in blue. KAT5 truncating mutations are shown in black. D. A model of KAT5 (shown in cyan) was generated in AlphaFold and aligned to the Esa1 chain (shown in dark blue) in a cryo-EM structure of the S. cerevisiae NuA4 core complex bound to the nucleosome (PDB ID: 7VVU). The other NuA4 core complex chains are colored as follows: Ep11 in green, Yng2 in orange, and Eaf6 in pink. The histones (H2A, H2B, H3, and H4) are colored in gold. Mutated KAT5 residues are shown in magenta. E. The side chain of R86 (R53 of isoform 2) is shown in magenta sticks and is located near the active site and 4.3 Å from acetyl-CoA (shown in bright green) that is bound to the 7VVU structure. F. R95 (R71 of isoform 2) is predicted to make interactions with E89 and Y80 to stabilize the tertiary structure of the chromodomain. G. Residues S333, E376, D378, and D529 are all clustered in the same region of the protein, which in Esa1 interacts with Ep11 in the NuA4 core complex. H. Residues N475, N496, and L495 cluster in a region of the protein that interacts with Ep11 and also facilitates interactions with the histones in the nucleosome.

Description

Accurate DNA damage repair is essential for genome maintenance and stability as inappropriate repair leads to accumulation of mutations and copy number variations (CNVs). Among the forms of genomic insults, the DNA double strand break (DSB) is one of the most lethal forms of damage because it severs the chromosome into two parts (Audrey et al., 2022). Left unrepaired, it often kills the cell while improper repair can produce small insertions and deletions (InDels) as well as large chromosomal re-arrangements such as inversions, deletions, duplications, translocations, fusions, and other complex architectural changes (Yoshioka et al., 2021). Such large-scale genomic changes are common in cancer cells and can affect global gene expression (Albertson et al., 2003; Cortes-Ciriano et al., 2020; Dahiya et al., 2022; Wang et al., 2020; Yi and Ju, 2018).

DSBs are repaired by two major mechanisms: Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR) (Audrey et al., 2022; Dahiya et al., 2022; Mehta and Haber, 2014). In human cells, NHEJ operates throughout the cell cycle while HR is generally restricted to S-phase and G2/M. The HR restriction to these cell stages is primarily due to the availability of the sister chromatid and the fact that certain HR genes are under the control of the cyclin dependent kinases, primarily CDK1 and CDK2 (Audrey et al., 2022; Kciuk et al., 2022). NHEJ is an error prone repair mechanism as it often results in microdeletions at the site of the lesion (Ghosh and Raghavan, 2021; Paull and Gellert, 1998; Seol et al., 2018). Conversely, HR has been traditionally billed as an error-proof mechanism (Amunugama and Fishel, 2012; Elbakry and Lobrich, 2021; Scully et al., 2019); however, we now know that certain HR pathways are error-prone (Guirouilh-Barbat et al., 2014).

In human cells, a battery of genes including the breast cancer susceptibility genes BRCA1 and BRCA2 work to favor most DSB repair towards error-free pathways (Gorodetska et al., 2019; Li et al., 2019; Roy et al., 2011; Yoshiida and Miki, 2004). Central to this form of repair is the loading of the RAD51 recombinase by BRCA2 (assisted by BRCA1 and PALB2) onto resected single stranded DNA to initiate invasion of the sister donor template by the broken chromosome end (Wang et al., 2022). Mutations in the BRCA1/2, RAD51 or PALB2 genes cause improper break repair and pose an increased risk of cancer (Yoshimura et al., 2022). Remarkably, in the absence of BRCA1/2 function, repair relies on RAD52, the central recombinase in yeast but an accessory gene in human cells (Jalan et al., 2019; Lodovichi et al., 2022; Patel et al., 2021; Rossi et al., 2021; Thorpe et al., 2011). RAD52 is able to substitute for the functions of BRCA1/2-PALB2 and load RAD51 to promote strand invasion but this pathway is error prone and leads to chromosomal re-arrangements.

Proper chromatin remodeling is also essential for preventing chromosomal rearrangements (Bakkenist and Kastan, 2015) and numerous factors have been identified that facilitate chromatin remodeling at DSBs (Caron et al., 2021; Karl et al., 2021). KAT5/TIP60 is a histone acetyltransferase belonging to a family of proteins with members in virtually all species studied (Yang, 2004). It has broad functions in DSB repair including acetylation of histone H4 which promotes chromatin remodeling and acetylation of ATM and p53 which results in activation of the DNA damage checkpoint and exchange of phosphorylated histone H2AX with unmodified H2AX (Avvakumov and Cote, 2007a, b; Hong et al., 2015; Lakhter et al., 2013; Wang and Chen, 2010). Changes in KAT5 gene expression has been correlated with cancer progression (Ahmad et al., 2021; Feng et al., 2014; Kim and Lee, 2019; McGuire et al., 2019; Tan et al., 2020; Wei et al., 2019; Yoshida et al., 2011) and small molecule inhibitors targeting KAT5 have already been developed (Brown et al., 2016; Coffey et al., 2012; Cregan et al., 2016; Ghizzoni et al., 2012; Wang et al., 2019). Thus, KAT5 is an important tumor suppressor.

We investigated the distribution of KAT5 point mutations in the reported cancers using the Catalogue of Somatic Mutations in Cancers (COSMIC) (Forbes et al., 2017; Forbes et al., 2015). Most coding mutations were missense or silent while only 14
were frameshift or stop codon (all frameshift mutations introduced a stop codon) (Fig.1A). Non-coding mutations (intronic, 3’ and 5’ UTR) were also identified. The large intestine was characterized by the highest frequency of mutations reported on COSMIC, but mutations were found in every cancer type, albeit at lower frequency (Fig.1B).

KAT5 is characterized by a chromodomain at its N-terminus, a zinc finger domain in the middle of the protein and a catalytic domain at its C-terminus (Fig.1C) (Li and Rasmussen, 2020; Sun et al., 2010). Chromodomains are chromatin interacting modules (Brehm et al., 2004; Taverna et al., 2007) and in the case of KAT5 it interacts with H3K9me3 (Li and Rasmussen, 2020; Sun et al., 2009). Certain mutations in the chromodomain affect KAT5 interaction with chromatin and its enzymatic activity (Sun et al., 2009). The MYST domain includes the catalytic site which can be further differentiated into a zinc finger domain and a HAT domain. MOZ represents a shared domain among a family of histone acetyltransferases named for the MOnocytic Leukemia Zink Finger (Perez-Campo et al., 2013). Several post-translational modifications that modulate the function of KAT5 have been identified (Li and Rasmussen, 2020).

At least four different isoforms of KAT5 have been identified (https://www.ncbi.nlm.nih.gov/gene/10524) (Kamine et al., 1996; Li and Rasmussen, 2020; Ran and Pereira-Smith, 2000). Isoform 2 is 513 amino acids and the major KAT5 isoform (Fig.1C). KAT5 functions as a subunit of a larger complex known as the NuA4 (Nucleosome Acetyltransferase of Histone H4) with roles in both transcription and DSB repair (Allard et al., 1999; Doyon and Cote, 2004; Doyon et al., 2004). In addition to its repair functions, the NuA4 complex also regulates transcription of certain genes. Therefore, KAT5 mutations in cancer cells can affect both DNA repair damage and gene expression.

Driver and pathogenic KAT5 mutations. An initial survey of the COSMIC data shows that KAT5 mutations distribute throughout the entire KAT5 coding sequence and although some amino acids are mutated at higher frequency, there is no obvious hotspot. However, not all mutations affect gene function equally. To understand the effect of the reported mutations on gene function, we employed two algorithms: the CHASMplus machine learning algorithm that classifies missense mutations as driver or passenger (Tokheim and Karchin, 2019), and the VEST4 machine learning algorithm that predicts the probability that a mutation is pathogenic (Douville et al., 2016). We used the Open CRAVAT website for this analysis (https://run.opencravat.org) (Masica et al., 2017). Both algorithms generate a p-value for each mutation which can be used to interpret significance. When we categorized those mutations with a significant p-value we found that they cluster primarily in the chromodomain or the active site of the protein (Fig.1C). This suggests that mutations in the linker region between the chromodomain and the zinc finger or between the zinc finger and the MOZ domain do not have a great effect on gene function. Remarkably, the algorithms predict that a lot of mutations are driver suggesting that altering the function of KAT5 is likely to promote cellular transformation and immortalization. Most driver mutations are also pathogenic. Only three mutations were identified that were pathogenic but not driver (Fig.1C). Several truncating mutations were also reported (Fig.1C). The algorithms do not predict the significance of these mutations, but truncating mutations are likely to have a severe effect on gene function.

Of note, we identified a D529N KAT5 mutation that is both driver (p=0.0328) and pathogenic (p=0.0493) that co-occurs with a RAD52 truncation (E320*) in a large intestine metastatic adenocarcinoma. Truncated C-terminus RAD52 alleles have been previously shown to suppress certain germline BRCA2 mutations (Adamson et al., 2020) and the E320* RAD52 truncation also co-occurs with BRCA2 mutations in human cancers (Hamid et al., 2022). Indeed, a BRCA2 E2599* mutation was also present in this patient as well as several BRCA1 mutations. Chromosomal re-arrangements including chromothripsis drive metastasis in colorectal cancers (Kloosterman et al., 2011) and this finding suggests that several repair pathways become destabilized.

Impact of mutations on protein structure/function. To model the impact that KAT5 mutations could have on protein structure and function, an AlphaFold (Jumper et al., 2021) model of human KAT5 was aligned to the recently deposited cryo-EM structure of the S. cerevisiae NuA4 core complex bound to the nucleosome (PDB ID: 7VVU) (Fig. 1D). This showed that the AlphaFold model of human KAT5 aligned very well with the experimentally determined structure of S. cerevisiae Esal homologue, with an RMSD value of 0.45 Å. AlphaFold was also able to model the N-terminal chromodomain with high confidence, which was not resolved in the cryo-EM structure or a previous crystal structure of the NuA4 core complex (PDB ID: 5J9U) (Xu et al., 2016). This alignment allowed us to predict whether mutations could impact protein-protein interactions within the NuA4 core complex, interactions with the nucleosome, or binding of acetyl-CoA. We identified nine driver or pathogenic mutations that are conserved in S. cerevisiae suggesting their evolutionary importance. Based on the protein modeling and alignments, several mutations are predicted to affect KAT5 protein structure and/or function. R86 was modeled with >70% confidence by AlphaFold and is predicted to interact with acetyl-CoA based on the alignments (Fig. 1E). The R86H mutation would disrupt this interaction. R86 is conserved in yeast, but this residue is not resolved in the published structures, so it is difficult to determine if this predicted interaction is correct. R95 is predicted to mediate tertiary structure interactions in the chromodomain (Fig. 1F) and a mutation to a hydrophobic and bulky tryptophan residue could disturb the
structure of this domain. S333, E376, D378, and D529 all cluster in the same area of the protein (Fig. 1G). However, only the S333F mutation is hypothesized to influence protein structure due to the hydrophobic nature of phenylalanine. This domain also makes contact with Epl1 in the NuA4 core complex, and thus mutations could affect this interaction. Another cluster of mutations occurs with N475, L495, and N496 (Fig. 1H). The N475 residue specifically is predicted to interact with a lysine residue in a partially resolved Epl1 loop in the cryo-EM structure. This Epl1 loop also mediates interactions with the nucleosome, making this domain particularly important.

**Conclusion.** Numerous KAT5 mutations have been identified in cancer cells and in this work we used established artificial intelligence algorithms to classify them as predicted pathogenic or driver. We further predicted the impact of these mutations through *in silico* modeling. These analyses may inform cancer therapies as driver mutations may be more likely to cause cellular transformation and immortality.

**Methods**

Excel files (.csv) with KAT5 mutations were downloaded from COSMIC (https://cancer.sanger.ac.uk/cosmic Version 95 on Monday, April 4th, 2022). To extract CHASM and VEST p-values the COSMIC files were processed using OPEN CRAVAT web version (https://www.opencravat.org/).

AlphaFold was used to generate a model of KAT5 isoform 2, which was then aligned to Esa1 in the cryo-EM structure of the *S. cerevisiae* NuA4 core complex bound to the nucleosome (PDB ID: 7VVU) using PyMOL (version 2.3.4). Homologous Esa1 residues were identified using the PyMOL alignment and the protein BLAST sequence alignment.

All figures were made in Photoshop.

**Acknowledgements:** We thank Susan Forsburg for reading our manuscript and for her scientific input.

**References**

Adamson AW, Ding YC, Mendez-Dorantes C, Bailis AM, Stark JM, Neuhausen SL. 2020. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations. Mol Oncol 14: 1124-1133. PubMed ID: [32175645](https://www.ncbi.nlm.nih.gov/pubmed/32175645)

Ahmad T, Ashraf W, Ibrahim A, Zaatyer L, Muller CD, Hamiche A, et al., Mousli M. 2021. TIP60 governs the auto-ubiquitination of UHRF1 through USP7 dissociation from the UHRF1/USP7 complex. Int J Oncol 59: . PubMed ID: [34558642](https://www.ncbi.nlm.nih.gov/pubmed/34558642)

Albertson DG, Collins C, McCormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nat Genet 34: 369-76. PubMed ID: [12923544](https://www.ncbi.nlm.nih.gov/pubmed/12923544)

Allard S, Utley RT, Savard J, Clarke A, Grant P, Brandl CJ, et al., Côté J. 1999. NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p. EMBO J 18: 5108-19. PubMed ID: [10487762](https://www.ncbi.nlm.nih.gov/pubmed/10487762)

Amunugama R, Fishel R. 2012. Homologous recombination in eukaryotes. Prog Mol Biol Transl Sci 110: 155-206. PubMed ID: [22749146](https://www.ncbi.nlm.nih.gov/pubmed/22749146)

Audrey A, de Haan L, van Vugt MATM, de Boer HR. 2022. Processing DNA lesions during mitosis to prevent genomic instability. Biochem Soc Trans 50: 1105-1118. PubMed ID: [36040211](https://www.ncbi.nlm.nih.gov/pubmed/36040211)

Avvakumov N, Côté J. 2007. Functions of myst family histone acetyltransferases and their link to disease. Subcell Biochem 41: 295-317. PubMed ID: [17484133](https://www.ncbi.nlm.nih.gov/pubmed/17484133)

Avvakumov N, Côté J. 2007. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26: 5395-407. PubMed ID: [17694081](https://www.ncbi.nlm.nih.gov/pubmed/17694081)

Bakkenist CJ, Kastan MB. 2015. Chromatin perturbations during the DNA damage response in higher eukaryotes. DNA Repair (Amst) 36: 8-12. PubMed ID: [26391293](https://www.ncbi.nlm.nih.gov/pubmed/26391293)

Brehm A, Tufteland KR, Aasland R, Becker PB. 2004. The many colours of chromodomains. Bioessays 26: 133-40. PubMed ID: [14745831](https://www.ncbi.nlm.nih.gov/pubmed/14745831)

Brown JA, Bourke E, Eriksson LA, Kerin MJ. 2016. Targeting cancer using KAT inhibitors to mimic lethal knockouts. Biochem Soc Trans 44: 979-86. PubMed ID: [27528742](https://www.ncbi.nlm.nih.gov/pubmed/27528742)
Caron P, Pobega E, Polo SE. 2021. DNA Double-Strand Break Repair: All Roads Lead to Heterochromatin Marks. Front Genet 12: 730696. PubMed ID: 34539757

Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, et al., Robson CN. 2012. Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One 7: e45539. PubMed ID: 23056207

Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, et al., PCAWG Consortium,. 2020. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet 52: 331-341. PubMed ID: 32025003

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG. 2016. KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. Int J Oncol 48: 1290-6. PubMed ID: 26780987

Dahiya R, Hu Q, Ly P. 2022. Mechanistic origins of diverse genome rearrangements in cancer. Semin Cell Dev Biol 123: 100-109. PubMed ID: 33824062

Douville C, Masica DL, Stenson PD, Cooper DN, Gygax DM, Kim R, Ryan M, Karchin R. 2016. Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST-Indel). Hum Mutat 37: 28-35. PubMed ID: 26442818

Elbakry A, Löbrich M. 2021. Homologous Recombination Subpathways: A Tangle to Resolve. Front Genet 12: 723847. PubMed ID: 3440877

Feng FL, Yu Y, Liu C, Zhang BH, Cheng QB, Li B, et al., Jiang XQ. 2014. KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9. Int J Clin Exp Pathol 7: 80-91. PubMed ID: 24427328

Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al., Campbell PJ. 2017. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45: D777-D783. PubMed ID: 27899578

Ghizzoni M, Wu J, Gao T, Haisma HJ, Dekker FJ, George Zheng Y. 2012. 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. Eur J Med Chem 47: 337-44. PubMed ID: 22100137

Ghosh D, Raghavan SC. 2021. Nonhomologous end joining: new accessory factors fine tune the machinery. Trends Genet 37: 582-599. PubMed ID: 33785198

Hamid AB, Frank LE, Bouley RA, Petreaca RC. 2022. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers. PLoS One 17: e0273736. PubMed ID: 36107942

Hong S, Dutta A, Laimins LA. 2015. The acetyltransferase Tip60 is a critical regulator of the differentiation-dependent amplification of human papillomaviruses. J Virol 89: 4668-75. PubMed ID: 25673709

Jalar M, Olsen KS, Powell SN. 2019. Emerging Roles of RAD52 in Genome Maintenance. Cancers (Basel) 11: . PubMed ID: 31340507

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al., Hassabis D. 2021. Highly accurate protein structure prediction with AlphaFold. Nature 596: 583-589. PubMed ID: 34265844

Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G. 1996. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 216: 357-66. PubMed ID: 8607265

Karl LA, Peritore M, Galanti L, Pfander B. 2021. DNA Double Strand Break Repair and Its Control by Nucleosome Remodeling. Front Genet 12: 821543. PubMed ID: 35096025
Kciuk M, Gielecińska A, Mujwar S, Mozycz M, Kontek R. 2022. Cyclin-dependent kinases in DNA damage response. Biochim Biophys Acta Rev Cancer 1877: 188716. PubMed ID: 35271993

Kim CH, Lee DH. 2019. KAT5 Negatively regulates the proliferation of prostate cancer LNCaP cells via the caspase 3-dependent apoptosis pathway. Anim Cells Syst (Seoul) 23: 253-259. PubMed ID: 31489246

Kloosterman WP, Hoogstraat M, Paling O, Tavakoli-Yaraki M, Renkens I, Vermaat JS, et al., Cuppen E. 2011. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol 12: R103. PubMed ID: 22014273

Lakhter AJ, Kanginakudru S, Warren S, Touloukian CE, Boissy RE, Naidu SR. 2013. Impaired PIASy-Tip60 signaling weakens activation of p53 in melanoma. Melanoma Res 23: 213-7. PubMed ID: 23624367

Li J, Sun H, Huang Y, Wang Y, Liu Y, Chen X. 2019. Pathways and assays for DNA double-strand break repair by homologous recombination. Acta Biochim Biophys Sin (Shanghai) 51: 879-889. PubMed ID: 31294447

Li Z, Rasmussen LJ. 2020. Tip60 in aging and neurodegeneration. Ageing Res Rev 64: 101195. PubMed ID: 33091598

Lodovichi S, Bellè F, Mercatanti A, Spugnesi L, Cozzani C, Calvio MA, Cervelli T, Galli A. 2022. RAD52 influences the effect of BRCA1/2 missense variants on homologous recombination and gene reversion in Saccharomyces cerevisiae. FEMS Yeast Res 22:. PubMed ID: 35472165

Masica DL, Douville C, Tokheim C, Bhattacharya R, Kim R, Moad K, Ryan MC, Karchin R. 2017. CRAVAT 4: Cancer-Related Analysis of Variants Toolkit. Cancer Res 77: e35-e38. PubMed ID: 29092935

McGuire A, Casey MC, Shalaby A, Kalinina O, Curran C, Webber M, et al., Brown JAL. 2019. Quantifying Tip60 (Kat5) stratifies breast cancer. Sci Rep 9: 3819. PubMed ID: 30846725

Mehta A, Haber JE. 2014. Sources of DNA double-strand breaks and models of recombinational DNA repair. Cold Spring Harb Perspect Biol 6: a016428. PubMed ID: 25104768

Patel PS, Algouneh A, Hakem R. 2021. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene 40: 3001-3014. PubMed ID: 33716297

Paull TT, Gellert M. 1998. The 3’ to 5’ exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks. Mol Cell 1: 969-79. PubMed ID: 9651580

Perez-Campo FM, Costa G, Lie-a-Ling M, Kouskoff V, Lacaud G. 2013. The MYSTERious MOZ, a histone acetyltransferase with a key role in haematopoiesis. Immunology 139: 161-5. PubMed ID: 23347099

Ran Q, Pereira-Smith OM. 2000. Identification of an alternatively spliced form of the Tat interactive protein (Tip60), Tip60(beta). Gene 258: 141-6. PubMed ID: 11111051

Rossi MJ, DiDomenico SF, Patel M, Mazin AV. 2021. RAD52: Paradigm of Synthetic Lethality and New Developments. Front Genet 12: 780293. PubMed ID: 34887904

Roy R, Chun J, Powell SN. 2011. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12: 68-78. PubMed ID: 22193408

Scully R, Panday A, Elango R, Willis NA. 2019. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol 20: 698-714. PubMed ID: 31263220

Seol JH, Shim EY, Lee SE. 2018. Microhomology-mediated end joining: Good, bad and ugly. Mutat Res 809: 81-87. PubMed ID: 28754468

Sun Y, Jiang X, Price BD. 2010. Tip60: connecting chromatin to DNA damage signaling. Cell Cycle 9: 930-6. PubMed ID: 20160506

Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR, Price BD. 2009. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 11: 1376-82. PubMed ID: 19783983

Tan KN, Avery VM, Carrasco-Pozo C. 2020. Metabolic Roles of Androgen Receptor and Tip60 in Androgen-Dependent Prostate Cancer. Int J Mol Sci 21:. PubMed ID: 32927797

Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. 2007. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 14: 1025-1040. PubMed ID: 17984965
Thorpe PH, Alvaro D, Lisby M, Rothstein R. 2011. Bringing Rad52 foci into focus. J Cell Biol 194: 665-7. PubMed ID: 21893595

Tokheim C, Karchin R. 2019. CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Cell Syst 9: 9-23.e8. PubMed ID: 31202631

Wang J, Chen J. 2010. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. J Biol Chem 285: 11458-64. PubMed ID: 20100829

Wang LT, Wang SN, Chioou SS, Liu KY, Chai CY, Chiang CM, et al., Hsu SH. 2019. TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. Oncogene 38: 518-532. PubMed ID: 30154425

Wang WI, Li LY, Cui JW. 2020. Chromosome structural variation in tumorigenesis: mechanisms of formation and carcinogenesis. Epigenetics Chromatin 13: 49. PubMed ID: 33168103

Wang Z, Jia R, Wang L, Yang Q, Hu X, Fu Q, et al., Ren Y. 2022. The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target. Front Oncol 12: 93593. PubMed ID: 35875146

Wei X, Cai S, Boohaker RJ, Fried J, Li Y, Hu L, et al., Xu B. 2019. KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC. Endocr Relat Cancer 26: 141-151. PubMed ID: 30400007

Xu P, Li C, Chen Z, Jiang S, Fan S, Wang J, et al., Chen Z. 2016. The NuA4 Core Complex Acetylates Nucleosomal Histone H4 through a Double Recognition Mechanism. Mol Cell 63: 965-75. PubMed ID: 27594449

Yang XJ. 2004. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32: 959-76. PubMed ID: 14960713

Yi K, Ju YS. 2018. Patterns and mechanisms of structural variations in human cancer. Exp Mol Med 50: 1-11. PubMed ID: 30089796

Yoshida K, Miki Y. 2004. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95: 866-71. PubMed ID: 15546503

Yoshida M, Ishimura A, Terashima M, Enkhbaatar Z, Nozaki N, Satou K, Suzuki T. 2011. PLU1 histone demethylase decreases the expression of KAT5 and enhances the invasive activity of the cells. Biochem J 437: 555-64. PubMed ID: 21574959

Yoshimura A, Imoto I, Iwata H. 2022. Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management. Int J Mol Sci 23: . PubMed ID: 35806485

Yoshioka KI, Kusumoto-Matsuo R, Matsuno Y, Ishiai M. 2021. Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair. Int J Mol Sci 22: . PubMed ID: 34830134

Funding: This project was funded by an NIH grant to RCP and RAB (R03CA252498-01A1). Additional funds were provided to RCP by The Ohio State University James Comprehensive Cancer Center Pelotonia Fund.

Author Contributions: Kimberly L Hardison: investigation, validation, visualization. Tila M Hawk: investigation. Renee A Bouley: formal analysis, investigation, writing - original draft, funding acquisition, conceptualization. Ruben C Petreaca: conceptualization, formal analysis, project, resources, supervision, writing - original draft, software, funding acquisition.

Reviewed By: Anonymous

History: Received November 10, 2022 Revision Received November 21, 2022 Accepted November 21, 2022 Published Online November 28, 2022 Indexed December 12, 2022

Copyright: © 2022 by the authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: L Hardison, K; M Hawk, T; A Bouley, R; C Petreaca, R (2022). KAT5 histone acetyltransferase mutations in cancer cells. microPublication Biology. 10.17912/micropub.biology.000676